產(chǎn)品詳情
簡(jiǎn)單介紹：
Anti-phospho-LKB1 (Thr363)抗體產(chǎn)品質(zhì)量穩(wěn)定，實(shí)驗(yàn)效果明顯，貨期快，價(jià)格優(yōu)惠，歡迎垂詢訂購！我公司長(zhǎng)期供應(yīng)**組化抗體、WB抗體、**組化試劑盒和抗體試驗(yàn)所需全部相關(guān)試劑、熒光標(biāo)記抗體、單克隆抗體、多克隆抗體、各種標(biāo)記的二抗IgG/IgM/IgD/IgA等科研實(shí)驗(yàn)抗體。Anti-phospho-LKB1 (Thr363)抗體用于**組化實(shí)驗(yàn),WB實(shí)驗(yàn),相應(yīng)的標(biāo)記抗體有HRP標(biāo)記抗體,FITC標(biāo)記,BIO等。
詳情介紹：
Rabbit Anti-phospho-LKB1 (Thr363)
Cat. Number:
Anti-phospho-LKB1 (Thr363)抗體KL-1532R
Quantity size:
0.1ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
This gene, which encodes a member of the serine/threonine kinase family, regulates cell polarity and functions as a tumor suppressor. Mutations in this gene have been associated with Peutz-Jeghers syndrome, an autosomalAnti-phospho-LKB1 (Thr363)抗體 dominant disorder characterized by the growth of polyps in the gastrointestinal tract, pigmented macules on the skin and mouth, and other neoplasms. Alternate transcriptional splice variants of this gene have been observed but have not been thoroughly characterized. [provided by RefSeq, Jul 2008].
Also known as:
LKB 1; LKB1; NY REN 19 antigen; Peutz Jeghers syndrome; PJS; Serine/Threonine Kinase 11; Serine/threonine protein kinase 11;Anti-phospho-LKB1 (Thr363)抗體 Serine/threonine protein kinase LKB1; STK 11; STK11; STK11_HUMAN.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Mouse, Anti-phospho-LKB1 (Thr363)抗體Rat, Chicken, Dog, Cow, Horse, .
●
Immunogen: KLH conjugated Synthesised phosphopeptide derived from human.
●
Predicted Molecular Weight: 48kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500
Not yet tested in other applications. Anti-phospho-LKB1 (Thr363)抗體
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications. Anti-phospho-LKB1 (Thr363)抗體
Optimal working dilutions must be determined by the end user.
